Posted by Michael Wonder on 16 Jul 2025
Nanoscope Therapeutics initiates rolling submission of biologics license application to FDA for MCO-010, the first gene-agnostic therapy to treat retinitis pigmentosa
14 July 2025 - First modules of biologics license application submitted to FDA under rolling review, with full submission anticipated in early 2026.
Nanoscope Therapeutics today announced the initiation of a rolling submission of a biologics license application to the US FDA for its lead investigational therapy, MCO-010, for the treatment of severe vision loss due to retinitis pigmentosa.
